The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article ... phase 1 study ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 URO-901-3005 trial.

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response to nucleic acids, according to a recent study.